Mammary Cell News 10.28 July 19, 2018 | |
| |
TOP STORYShieldin Complex Promotes DNA End-Joining and Counters Homologous Recombination in BRCA1-Null Cells Investigators showed that C20orf196 and FAM35A form a complex, ‘Shieldin’, with FAM35A interacting with single-stranded DNA through its C-terminal oligonucleotide/oligosaccharide-binding fold region. Shieldin acted as the downstream effector of 53BP1/RIF1/MAD2L2 to promote DNA double-strand break (DSB) end-joining by restricting DSB resection and to counteract homologous recombination by antagonizing BRCA2/RAD51 loading in BRCA1-deficient cells. [Nat Cell Biol] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)MS645 blocked BRD4 binding to transcription enhancer/mediator proteins MED1 and YY1 with potency superior to monovalent BET inhibitors, resulting in down-regulation of proinflammatory cytokines and genes for cell-cycle control and DNA damage repair that are largely unaffected by monovalent bromodomain inhibition. [Proc Natl Acad Sci USA] Abstract Activating transcription factor 4 (ATF4) overexpression correlated with triple negative breast cancer patient survival decrease and a SMAD-dependent crosstalk between ATF4 and TGFβ was identified. ATF4 expression inhibition reduced migration, invasiveness, mammosphere-forming efficiency, proliferation, epithelial-mesenchymal transition, and antiapoptotic and stemness marker levels. [Clin Cancer Res] Abstract Regulating BRCA1 Protein Stability by Cathepsin S-Mediated Ubiquitin Degradation Activating cathepsin S (CTSS) by radiation induced proteolytic degradation of BRCA1, which ultimately suppressed DNA double-strand break repair activity. Depletion of CTSS by RNAi or expression of a mutant type of CTSS enhanced the protein stability of BRCA1 by inhibiting its ubiquitination. Treatment with a pharmacological CTSS inhibitor inhibited proteolytic degradation of BRCA1 and restored BRCA1 function. [Cell Death Differ] Full Article Suppression of PDHX by MicroRNA-27b Deregulates Cell Metabolism and Promotes Growth in Breast Cancer By suppressing PDHX, miR-27b altered levels of pyruvate, lactate and citrate, as well as reduced mitochondrial oxidation and promoted extracellular acidification. These changes corresponded with an increased capacity for cell proliferation. [Mol Cancer] Full Article | Press Release Researchers developed a two-photon ratiometric probe for detecting carboxylesterase-2 (CE2) activity using succinate ester as a recognition site for CE2. The probe showed high selectivity to CE2, a clear emission color change, high photostability, and bright two-photon microscopy imaging capability, allowing the quantitative detection of CE2 activity in live cells. [Anal Chem] Abstract Scientists revealed that expression of TGFBR2 and MET was increased in basal‐like breast cancer cell lines, as well as in triple‐negative breast cancer tumor tissues, compared to other subtypes. They demonstrated that TGFβ1 triggered HGF‐induced and MET‐dependent migration in vitro. [Mol Oncol] Abstract | Full Article MiR-4319 could suppress the self-renewal and formation of tumorspheres in triple negative breast cancer (TNBC) cancer stem cells (CSCs) through E2F2, and also inhibited tumor initiation and metastasis in vivo. Increased E2F2 could reverse the effect of miR-4319 on the self-renewal in TNBC CSCs. [Cell Physiol Biochem] Full Article Researchers demonstrated that miR-410 inhibited breast cancer cell proliferation, migration and invasion, but promoted cell apoptosis. However, inhibition of miR-410 resulted in opposite effects. A xenograft nude mouse model further confirmed that miR-410 suppressed breast tumor growth. [Cell Physiol Biochem] Full Article Investigators demonstrated that R-goniothalamin triggered the appearance of a wild-type-like p53 protein by using conformation-specific antibodies, immunoprecipitation, DNA-binding assays and target gene expression. p53 restoration was associated with a G2/M arrest, senescence, reduced cell migration, invasion and increased cell death. [Carcinogenesis] Abstract Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSCurrent Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer The authors focus on the current knowledge of fibroblast growth factor receptor (FGFR) mutations, which lead to tumor formation and summarize the state-of-the-art therapeutic strategies for targeted treatments against the FGFRs/FGFs axis in the context of breast cancer. [Cells] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSPuma Biotechnology, Inc., and Strata Oncology, Inc., have entered into a collaborative agreement to accelerate patient enrollment in Puma’s ongoing Phase II SUMMIT trial of PB272. The SUMMIT trial is a global, multi-histology, open-label, precision-medicine ‘basket’ study evaluating the safety and efficacy of neratinib in patients with a wide variety of solid tumors with activating EGFR, HER2 or HER4 mutations. [STRATA ONCOLOGY, INC.] Press Release Novartis announced a new approval for Kisqali® from the FDA for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer. [Novartis AG] Press Release Genexine, announced that Hyleukin-7, their investigational T cell amplifier, has been selected for inclusion in the Korea Drug Development Fund’s new drug development project. Genexine will conduct a Phase Ib/II clinical trial to investigate the safety and efficacy of Hyleukin-7 treatment in combination with Merck’s anti PD-1 therapy, KEYTRUDA® in patients with triple-negative breast cancer. [Genexine, Inc.] Press Release | |
| |
POLICY NEWSOnline Portal of Thousands of Clinical Trials Could Aid Disease Research Under pressure to be more transparent about the results of drug testing studies, some companies have begun to share anonymized patient data from clinical trials with approved researchers on secure websites. An online platform launched aims to expand such efforts by offering a one-stop clearinghouse for those seeking to mine these data for new insights. [ScienceInsider] Editorial Dutch Publishing Giant Cuts Off Researchers in Germany and Sweden Elsevier stopped thousands of scientists in Germany from reading its recent journal articles, as a row escalates over the cost of a nationwide open-access agreement. The move comes just two weeks after researchers in Sweden lost access to the most recent Elsevier research papers, when negotiations on its contract broke down over the same issue. [Nature News] Editorial New Policy Aims to Free Scientists to Focus on Research, Avoid Jumping through Hoops Chinese scientific researchers are to be evaluated on the valuable contributions they make to their field rather than their number of published papers or academic credentials, according to a new policy issued by China’s top officials. The new policy is considered by experts to be the first volley of China’s resistance to efforts by the U.S. to suppress its high-tech development. [Chinanews.com] Editorial
| |
EVENTSNEW San Antonio Breast Cancer Symposium 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Training Fellow – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Position – Breast Cancer (University of Trento) Cancer Faculty Investigators – Basic & Translational Cancer Research (The University of Alabama) Postdoctoral Fellow – Molecular Mechanisms of Breast & Colon Cancers (Dalhousie University) Post-doctoral Fellow – Ovarian and Breast Cancers (John Hopkins University) Postdoctoral Research Associate – Breast Cancer (Howard University) Cancer Scientists – Breast Cancer Research (Qatar Biomedical Research Institute) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|